IMGN853: Phase I started

ImmunoGen began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV IMGN853 given on day 1 of a 21-day cycle in about 64 patients with previously treated ovarian cancer, NSCLC or other e...